Metformin has been shown to improve the prognosis of pancreatic cancer by inhibiting the mTOR pathway, leading to decreased energy consumption and cell growth and increasing insulin sensitivity, causing decreased blood glucose levels. Here, MTOR is linked to familial pancreatic carcinoma.